Structure and function of immunoglobulins

Sepsis

Volumn 3, Issue 3, 1999, Pages 197-218

  Späth, Peter J ^a  

^a Central Laboratory in Bern   (Switzerland)

Author keywords

Attenuation of inflammation; Complement; Host defense; IgA; IgG; IgM; Immunoglobulins; Intravenous immunoglobulin; Structure and function; Therapy

Indexed keywords

AUTOANTIBODY; COMPLEMENT; CROSS REACTING ANTIBODY; CYTOKINE; EPITOPE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; GERM LINE; HOST RESISTANCE; IMMUNITY; IMMUNOGLOBULIN STRUCTURE; IMMUNOMODULATION; INFLAMMATION; RETICULOENDOTHELIAL SYSTEM; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0343485064     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009899803032     Document Type: Article

References (175)

1. Fearon DT. Seeking wisdom in innate immunity. Nature 1997;388:323-324.
2. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272:50-54.
3. Bendelac A, Fearon DT. Innate immunity - Innate pathways that control acquired immunity. Curr Opin Immunol 1997;9:1-3.
4. Turner MW, Knox L. The subclasses of human immunoglobulin G. Immunol Today 1980;1:inserted folder.
5. Nomenclature for human immunoglobulin. Bull World Health Organ 1964;30:447-449.
6. Rowe DS. IgD: A new class of human immunoglobulins. G Mal Infett Parassit 1966;18:Suppl-2.
7. Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966;97:75-85.
8. Nomenclature of human immunoglobulins. Bull World Health Organ 1973;48:373-374.
9. Porter RR. Separation and isolation of fractions of rabbit gammaglobulin containing the antigenic combining sites. Nature 1958;182:670-671.
10. Porter RR. γ-Globulin and antibodies. In: Putnan A, ed. The Plasma Proteins: Isolation Characterization and Function. 1960:241-271.
11. Brambell FWR, Hemmings WA, Porter RR. The relative transmission of the fractions of papain hydrolyzed homologous γ-globulin from the uterine cavity to the foetal circulation in the rabbit. Proc Royal Soc London Series B 1960;151: 478-482.
12. Porter RR. Structural studies of immunoglobulins. Science 1973;180:713-716.
13. Edelman GM, Cunningham BA, Gall WE, et al. The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci USA 1969;63:78-85.
14. Kabat EA, Wu TT, Bilofsky H. Evidence supporting somatic assembly of the DNA segments (minigenes), coding for the framework, and complementarity-determining segments of immunoglobulin variable regions. J Exp Med 1979;149:1299-1313.
15. Unkeless JC, Shen Z, Lin CW, et al. Function of human Fc gamma RIIA and Fc gamma RIIIB. Semin Immunol 1995; 7:37-44.
16. Shohet JM, Pemberton P, Carrol MC. Identification of a major binding site for complement C3 in the IgG1 heavy chain. J Biol Chem 1993;268:5866-5871.
17. Anton LC, Ruiz S, Barrio E, et al. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates. Eur J Immunol 1994;24:599-604.
18. Lutz HU, Bussolino F, Flepp R, et al. Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci USA 1987;84:7368-7372.
19. 18a. Jelezarova E, Lutz HU. Assembly and regulations of the complement amplification loop in blood: The role of C3b-C3b-IgG complexes. Mol Immunol 1999; submitted.
20. Yang KD, Bathras JM, Shigeoka AO, et al. Mechanisms of bacterial opsonization by immune globulin intravenous: correlation of complement consumption with opsonic activity and protective efficacy. J Infect Dis 1989;159:701-707.
21. Smith CL, Baker CJ, Anderson DC, et al. Role of complement receptors in opsonophagocytosis of group-B streptococci by adult and neonatal neutrophils. J Infect Dis 1990; 162:489-495.
22. Ross C, Densen P. Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine Baltimore 1984;63:243-273.
23. Schoolnik GK, Buchanan TM, Holmes KK. Gonococci causing disseminated infection are restistant to the bactericidal action of normal human serum. J Clin Invest 1976;58:1163-1173.
24. McCabe WR, Kaijser B. Olling S, et al. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains form adults and neonates. J Infect Dis 1978;138: 33-41.
25. Casciato DA, Rosenblatt JE, Bluestone R, et al. Susceptibility of isolates of bacteroides to the bactericidal activity of normal human serum. J Infect Dis 1979;140:109-113.
26. Wilkinson BJ, Sisson SP, Kim Y, et al. Localization of the third component of complement on the cell wall of encapsulated Staphylococcus aureus M: implications for the mechanisms of resistance to phagocytosis. Infect Immun 1979;26: 1159-1163.
27. Winkelstein JA, Abramovitz AS, Tomasz A. Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall. J Immunol 1980; 124:2502-2506.
28. Durack DT, Beeson PB. Protective role of complement in experimental Escherichia coli endocarditis. Infect Immun 1977;213-217.
29. Miller TE, Phillips S, Simpson IJ. Complement-mediated immune mechanisms in renal infection. II. Effect of decomplementation. Clin Exp Immunol 1978;33:115-121.
30. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988;332:738-740.
31. Tao MH, Canfield SM, Morrison SL. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med 1991;173:1025-1028.
32. Arya S, Chen F, Spycher S, et al. Mapping of amino acid residues in the C mu 3 domain of mouse IgM macromolecular assembly and complement-dependent cytolysis. J Immunol 1994;152:1206-1212.
33. Taylor B, Wright JF, Arya S, et al. C1q binding properties of monomer and polymer forms of mouse IgM mu-chain variants - Pro544Gly and Pro434Ala. J Immunol 1994;153: 5303-5313.
34. Chen FH, Arya SK, Rinfret A, et al. Domain-switched mouse IgM/IgG2b hybrids indicate individual roles for C2, C3, and C4 domains in the regulation of the interaction of IgM with complement C1q. J Immunol 1997; 159:3354-3363.
35. Sim RB, Reid KBM. C1 Molecular interactions with activating systems. Immunol Today 1991;12:307-311.
36. Perkins SJ, Nealis AS, Sutton BJ, et al. Solution structure of human and mouse immunoglobulin-M by synchrotron X-ray scattering and molecular graphics modelling - A possible mechanism for complement activation. J Mol Biol 1991; 221:1345-1366.
37. Ratnoff WD, Fearon DT, Austen KF. The role of antibody in the activation of the alternative complement pathway. Springer Sem Immunopathol 1983;6:361-371.
38. Joiner KA, Warren KA, Tam M, et al. Monoclonal antibodies directed against gonococcal protein I vary in bactericidal activity. J Immunol 1985;134:3411-3419.
39. Fredlund H, Sjoholm AG, Selander B, et al. Serum bactericidal activity and induction of chemiluminescence of polymorphonuclear leukocytes: Complement activation pathway requirements in defense against Neisseria meningitidis. Int Arch Allergy Immunol 1993;100:135-143.
40. Fries LF, Siwik SA, Malbran A, et al. Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leucocytes. Immunology 1987; 62:45-45.
41. Schifferli JA, Barlotti SR, Peters DK. Inhibition of immune precipitation by complement. Clin Exp Immunol 1980;45: 387-394.
42. Schifferli JA, Ng YG, Peters DK. The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 1986;315:488-495.
43. Schifferli JA, Peters DK. Complement, the immune-complex lattice, and the pathophysiology of complement-deficiency syndromes. Lancet 1983;II:957-959.
44. Lutz HU. How pre-existing, germline-derived antibodies and complement may help induce a primary immune response to nonself. Scand J Immunol 1999;49:224-228.
45. Hayakawa K, Asano M, Shinton SA, et al. Positive selection of natural autoreactive B cells. Science 1999;285:113-116.
46. Avrameas S. Natural autoantibodies: From 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 1991;12:154-159.
47. Varela FJ, Coutinho A. Second generation immune networks. Immunol Today 1991;12:159-166.
48. Melchers, F. Introduction to the annual report: 1998. Basel. Basel Institute for Immunology - Annual Report 1999: pp. 1-17.
49. Donze HH, Lue C, Julian BA, et al. Human peritoneal B-1 cells and the influence of continuous ambulatory peritoneal dialysis on peritoneal and peripheral blood mononuclear cell (PBMC) composition and immunoglobulin levels. Clin Exp Immunol 1997;109:356-361.
50. + B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today 1989;10:364-368.
51. Brambell FWR, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature 1964;203:1352-1355.
52. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 1996;93:5512-5516.
53. 2-microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J Immunol 1997;159:4781-4792.
54. Raghavan M, Wang Y, Bjorkman PJ. Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. Proc Natl Acad Sci USA 1995;92:11200-11204.
55. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 199;340:227-228.
56. Raghavan M, Gastinel LN, Bjorkman PJ, The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. Biochemistry 1993;32:8654-8660.
57. Leach JL, Sedmak DD, Osborne JM, et al. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: Implications for maternal-fetal antibody transport. J Immunol 1996;157:3317-3322.
58. Sitia R, Rabellino EM, Sockell M, et al. A spatial association between membrane IgD and the receptor for C3b (CR1) at the cell surface on murine B lymphocytes. J Immunol 1981; 126:107-112.
59. Forsgren A, Grubb AO. Many bacterial species bind human IgD. J Immunol 1979;122:1468-1472.
60. Henney CS, Welschester HD, Terry WD, et al. Studies on human IgD. II. The lack of skin sensitizing and complement fixing activities of immunoglobulin D. Immunochemistry 1969;6:445-449.
61. Konno T, Hirai H, Inai S. Studies in IgD-I. Complement fixing activities of IgD myeloma proteins. Immunochemistry 1975;12:773-777.
62. Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimmore) 1994;73:133-144.
63. Boom BW, Daha MR, Vermeer BJ, et al. IgD immune complex vasculities in a patient with hyperimmunoglobulinemia D and periodic fever. Arch Dermatol 1990;126:1621-1624.
64. Kumano Y, Nagato T, Kurihara K, et al. Hyperimmunoglobulinemia D in idiopathic retinal vasculitis. Graefes Arch Clin Exp Ophthalmol 1997;235:372-378.
65. Saarinen UM, Strandjord SE, Warkentin PI, et al. Differentiation of presumed sepsis from acute graft-versus-host disease by C-reactive protein and serum total IgE in bone marrow transplant recipients. Transplantation 1987;44:540-546.
66. Dipiro JT, Howdieshell TR, Hamilton RG, et al. Immunoglobulin E and eosinophil counts are increased after sepsis in trauma patients. Crit Care Med 1998;26:465-469.
67. Dipiro JT, Hamilton RG, Howdieshell TR, et al. Lipopolysaccharide-reactive immunoglobulin E is associated with lower mortality and organ failure in traumatically injured patients. Clin Diagn Lab Immunol 1994;295-298.
68. Römer J, Morgenthaler J-J, Scherz R, et al. Characterizations of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang 1982;42:62-73.
69. Römer J, Späth PJ, Skvaril F, et al. Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to staphylococcus protein A. Vox Sang 1982;42:74-80.
70. Jungi TW, Santer M, Lerch PG, et al. Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. Vox Sang 1986;51:18-26.
71. Wiersma EJ, Shulman MJ. Assembly of IgM. Role of disulfide bonding and noncovalent interactions. J Immunol 1995;154:5265-5272.
72. Wiersma EJ, Chen F, Bazin R, et al. Analysis of IgM structures involved in J chain incorporation. J Immunol 1997;158: 1719-1726.
73. Dempsey PW, Allison MED, Akkaraju S, et al. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 1996;271:348-350.
74. Tridandapani S, Kelley T, Cooney D, et al. Negative signaling in B cells: SHIP Grbs She. Immunol Today 1997;18:424-427.
75. Poon PH, Phillips ML, Schumaker VN. Immunoglobulin M possesses two binding sites for complement subcomponent C1q, and soluble 1:1 and 2:1 complexes are formed in solution at reduced strength. J Biol Chem 1985;260:9357-9365.
76. Feinstein A, Richardson N, Taussig MJ. Immunoglobulin flexibility in complement activation. Immunol Today 1986;7: 169-174.
77. Painter RH. The binding of C1q to immunoglobulins. Behring Inst Mitt 1993;131-137.
78. Shigeoka AO, Jensen CJ, Pincus SH, et al. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci. J Infect Dis. 1984;150:63-70.
79. Stephan W, Dichtelmueller H, Schedel I. Eigenschaften und Wirksamheit eines humanen Immunoglobulin M-Präparates für die intravenöse Anwendung. Arzneim Forsch/Drug Res 1985;35:933-936.
80. Gronski P, Hofstaetter T, Kanzy EJ, et al. S-Sulfonation: A reversible chemical modification of human immunoglobulin permitting intravenous application. I. Physicochemical and binding properties of S-sulfonated and reconstituted IgG. Vox Sang 1983;45:144-154.
81. Davis AC, Shulman MJ. IgM - Molecular requirements for its assembly and function. Immunol Today 1989;10:118-122.
82. Behre G, et al. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulin in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial. Antiinfect Drugs Chemother 1995;13:129-134.
83. Borleffs JC, Schellekens JF, Brouwer E, et al. Use of an immunoglobulin M containing preparation for treatment of two hypogammaglobulinemic patients with persistent Campylobacter jejuni infection. Eur J Clin Microbiol Infect Dis 1993;12:772-775.
84. Haque KN, Zaidi MH, Bahakim H, IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am J Dis Child 1988;142:1293-1296.
85. Pilz G, Appel R, Kreuzer E, et al. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest 1997;111:419-426.
86. Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of gram-negative septic shock with an immunoglobolin preparation: A prospective, randomized clinical trial. Crit Care Med 1991;19:1104-1113.
87. Haque KN, Remo C, Bahakim H. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin Exp Immunol 1995;101:328-333.
88. Jackson SK, Parton J, Barnes RA, et al. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 1993;23:540-545.
89. Poynton CH, Jackson S, Fegan C, et al. Use of IgM-enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplant 1992;9:451-457.
90. Trautmann M, Held TK, Susa M, et al. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM-enriched product. Clin Exp Immunol 1998;111:81-90.
91. Ng PK, O'Rourke PE, Andersen JD, et al. Process-scale purification of immunoglobulin M concentrate. Vox Sang 1993;65:81-86.
92. Bubb MO, Conradie JD. The importance of quaternary structure in the expression of the C1-binding site of IgM. Immunology 1976;31:893-902.
93. Tsay GC, Jesmok G. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation. Miles Inc., Berkley Calif. United States Patent Oct, 26(5,256,771). 1993.
94. Tsay GC, Jesmok G. Heat-treated IgM antibody preparations. Bayer Corporation, Elkhart Ind. (5,510,465), 1-14. 1996.
95. Barandun S, Kistler P, Jeunet F, et al. Intravenous administration of human gammaglobulin. Vox Sang. 1962;7:157-174.
96. Pollack M, Koles NL, Preston MJ, et al. Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide. Infect Immun 1995;63:4481-4487.
97. Pier GB, Thomas DM. Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa. J Infect Dis 1983;148:206-213.
98. Kaufman BM, Cross AS, Futrovsky SL, et al. Monoclonal antibodies reactive with K1-encapsulated Escherichia coli lipopolysaccharide are opsonic and protect mice against lethal challenge. Infect Immun 1986;52:617-619.
99. Kim KS, Kang JH, Cross AS, et al. Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. J Infect Dis 1988; 157:47-53.
100. Pier GB, Thomas D, Small G, et al. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide. Infect Immun 1989;57:174-179.
101. Oishi K, Koles NL, Guelde G, et al. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide - Relation to antibody isotype and complement-fixing activity. J Infect Dis. 1992;165:34-45.
102. Foreman KE, Bjornson AB. The alternative complement pathway promotes IgM antibody-dependent and -independent adherence of Bacteroides to polymorphonuclear leukocytes through CR3 and CR1. J Leukoc Biol 1994;55: 603-611.
103. Bjornson AB, Detmers PA. The pentameric structure of IgM is necessary to enhance opsonization of Bacteroides thetaiotaomicron and Bacteroides fragilis via the alternative complement pathway. Microb Pathog 1995;19:117-128.
104. Mostov KE, Deitcher DL. Polymeric immunoglobulin receptor expressed in MDCK cells transcytoses IgA. Cell 1986; 46:613-621.
105. Mestecky J, McGhee JR. Immunoglobulin-A (IgA) - Molecular and cellular interactions involved in IgA biosynthesis and immune response. In: Dixon FJ, ed. Advances in Immunology. Orlando: Academic Press Inc., 1987:153-245.
106. Underdown BJ, Schiff JM. Immunoglobulin A: Strategic defense initiative at the mucosal surface. Annu Rev Immunol 1986;4:389-417.
107. Dickinson EC, Gorga JC, Garrett M, et al. Immunoglobulin A supplementation abrogates bacterial translocation and preserves the architecture of the intestinal epithelium. Surgery 1998;124:284-290.
108. Maxson RT, Jackson RJ, Smith SD. The protective role of enteral IgA supplementation in neonatal gut origin sepsis. J Pediatr Surg 1995;30:231-233.
109. Daha MR, Gorter A, Rits M, et al. Interaction of immunoglobulin-A with complement and phagocytic cells. Prog Clin Biol Res 1989;297:247-261.
110. Nikolova EB, Tomana M, Russell MW. The role of the carbohydrate chains in complement (C3) fixation by solid-phase-bound human IgA. Immunology 1994;82:321-327.
111. Zhang W, Lachmann PJ. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes. Immunology 1994;81:137-141.
112. Eibl MM, Wolf HM, Furnkranz H, et al. Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N Engl J Med 1988;319:1-7.
113. Hemmingsson P, Hammarström L. Nasal administration of immunoglobulin as effective prophylaxis against infections in elite cross-country skiers. Scand J Infect Dis 1993;25:783-785.
114. Lindberg K, Berglund B. Effect of treatment with nasal IgA on the incidence of infectious disease in world-class canoeists. Int J Sports Med 1996;17:235-238.
115. Cohn EJ, Strong LE, Hughes WLJ, et al. Preparation and properties of serum and plasma proteins. 1. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68:459-475.
116. Oncley JL, Melin M, Richert DA, et al. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and 1-lipoprotein into subfractions of human plasma. J Am Chem Soc 1949;71:541-550.
117. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722-728.
118. Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: Implications for therapeutic efficacy. Clin Infect Dis 1998;26:631-638.
119. Kroese FG, de Waard R, Bos NA. B-1 cells and their reactivity with the murine intestinal microflora. Semin Immunol 1996;8:11-18.
120. Bos NA, Bun JC, Popma SH, et al. Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria. Infect Immun 1996;64: 616-623.
121. Griffiss JM, Jarvis GA. Interaction of serum IgA with complement components: The molecular basis of IgA blockade. Adv Exp Med Biol 1987;216B:1303-1309.
122. Joiner KA, Scales R, Warren KA, et al. Mechanism of action blocking immunoglobulin-G for neisseria-gonorrhoeae. J Clin Invest 1985;76:1765-1765.
123. Rice PA, Vayo HE, Tam RM, et al. Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J Exp Med 1986;164:1735-1748.
124. Rice PA, McQuillen DP, Gulati S, et al. Serum resistance of Neisseria gonorrhoeae. Does it thwart the inflammatory response and facilitate the transmission of infection? Ann NY Acad Sci 1994;730:7-14.
125. Hamadeh RM, Estabrook MM, Zhou P, et al. Anti-Gal binds to pili of Neisseria meningitidis: The immunoglobulin A isotype blocks complement-mediated killing. Infect Immun 1995;63:4900-4906.
126. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T-cells by staphylococcal toxin superantigens J Clin Invest 1993;91:602-607.
127. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - A comparative observational study. Clin Infect Dis 1999;28:800-807.
128. Leung DYM. Kawasaki syndrome: Immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol 1996;104:49-54.
129. Imbach P, Barandun S, D'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-1231.
130. National Institute of Health (NIH) Consensus Development Conference. Intravenous immunoglobulin - Prevention and treatment of disease. JAMA 1990;264:3189-3193.
131. Iwata M, Shimozato R, Tokiwa H, et al. Antipyretic activity of human immunoglobulin in preparation for intravenous use (IGIV) in experimental model of fever in rabbits. In: Morell A, Nydegger UE, eds. Clinical Use of Intravenous Immunoglobulin. London: Academic Press, 1986:327-338.
132. Lam L, Whitsett CF, McNicholl JM, et al. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342:678-678.
133. Kekow J, Reinhold D, Pap T, et al. Intravenous immunoglobulins and transforming growth factor β. Lancet 1998; 351:184-185.
134. Abe Y, Horiuchi A, Miyake M, et al. Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-9.
135. Bendtzen K, Svenson M, Hansen M. Autoantibodies to cytokines in IVIG. J Rheumatol 1993;20:2176-2177.
136. Bendtzen K. Autoantibodies to cytokines. Eur J Clin Invest 1998;28:300-301.
137. Andersson U, Bjoerk L, Skansen-Saphir U, et al. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994;139:21-42.
138. Modiano JF, Amran D, Lack G, et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin. Clin Immunol Immunopathol 1997;83:77-85.
139. Nachbaur D, Herold M, Eibl B, et al. A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 1997;90:212-218.
140. Amran D, Renz H, Lack G, et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994;73:180-186.
141. Schanz U, Hügle T, Gmür J. Additional inhibitory effects of intravenous immunoglobulins in combination with cyclosporine A on human T lymphocyte alloproliferative response in vitro. Transplantation 1996;61:1736-1740.
142. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-2143.
143. Sewell WA, North ME, Cambronero R, et al. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol 1999;116:509-515.
144. Aukrust P, Müller F, Svenson M, et al. Administration of intravenous immunoglobulin (IVIG) in vivo-Down-regulatory effects on the IL-1 system. Clin Exp Immunol. 1999; 115:136-143.
145. Sharief MK, Ingram DA, Swash M, et al. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 1999;52:1833-1838.
146. 144a. Emmenegger U, Frey U, Reimers A, Cottagnoud P. Späth PJ, Neftel KA. Serum ferritin levels and emergency treatment with intravenous immunoglobulin in fulminant reactive macrophage activation syndromes, submitted.
147. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
148. Furusho K, Sato K, Soeda T, et al. High dose intravenous gammaglobulin for Kawasaki disease. Lancet 1983;II: 1359-1359.
149. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997;95:2476-2478.
150. Wolf HM, Eibl MM. The anti-inflammatory effect of an oral immunoglobulin (IgA-IgG) preparation and its possible relevance for the prevention of necrotizing enterocolitis. Acta Paediatr Suppl 1994;396:37-40.
151. Wolf HM, Vogel E, Fischer MB, et al. Inhibition of receptor-dependent and receptorindependent generation of the respiratory burst in human neutrophils and monocytes by human serum IgA. Pediatric Res 1994;36:235-243.
152. Wolf HM, Hauber I, Gulle H, et al. Anti-inflammatory properties of human serum IgA: Induction of IL-1 receptor antagonist and (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-alpha) and IL-6 in human monocytes. Clin Exp Immunol 1996;105:537-543.
153. Nachbaur D, Herold M, Gächter A, et al. Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin). Immunology 1998;94: 279-283.
154. Nezlin R, Freywald A. Complexes of IgG molecules and C3a and C4a complement components in human serum. Eur J Immunol 1992;22:1955-1957.
155. Nezlin R. Detection of the C3a complement component in commercial gamma-globulins by dot blotting. J Immunol Meth 1993;163:269-272.
156. Jacobs RJ, Reichlin M. Generation of low m.w., C3-bearing immunoglobulin in human serum. J Immunol 1983;130: 2775-2781.
157. Lutz HU, Stammler P, Fasler S. Preferential formation of C3b-IgG complexes in vitro and in vivo from nascent C3b and naturally occurring anti-band 3 antibodies. J Biol Chem 1993;268:17418-17426.
158. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol. 1992; 62:S82-S86
159. Basta M, Kirshbom P, Frank MM, et al. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974-1981.
160. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
161. n-IgG complexes. Blood 1996;88:184-193.
162. Miletic VD, Hester CG, Frank MM. Regulation of complement activity by immunoglobulin. 1. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 1996;156:749-757.
163. Rieben R, Roos A, Muizert Y, et al. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999;93:942-951.
164. Scholer A, Fischbach F, Spichiger U, et al. Einheitliche Referenzbereiche (Normwerte) für häufige klinisch-chemische Messgrössen. Schweizerische Ärztezeitung 1998;79:2619-2622.
165. Hurez V, Kazatchkine MD, Vassilev T, et al. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 1997;90: 4004-4013.
166. Hurez V, Kaveri S-V, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg). Therap Immunol 1994;1: 269-277.
167. Vassilev T, Gelin C, Kaveri S-V, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92:369-372.
168. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:865-869.
169. Hurez V, Kaveri SV, Kazatchkine MD. Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol 1993;23:783-789.
170. Marchalonis JJ, Kaymaz H, Dedeoglu F, et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta-chain. Proc Natl Acad Sci USA 1992;89:3325-3329.
171. Prasad NKA, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998;161:3781-3790.
172. Williams MA, Rhoades CJ, Lewis A, et al. Intravenous immunoglobulin blocks nitric oxide synthesis and activation-induced apoptosis in THP-1 macrophage cells. J Haematol 1999;84:254-255 (Abstract).
173. Brand A, Vuist WM, Van Schaik IN, et al. In vitro investigation of immunoglobulin treatment mechanisms in autoimmune diseases. Clin Exp Rheumatol 1996;14(Suppl 15):S27-S30
174. Vassilev TL, Kazatchkine MD, Van Huyen JP, et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999;93:3624-3631.
175. Terness P, Opelz G. Natural anti-immunoglobulin autoantibodies: Irrelevant by-products or immunoregulatory molecules? Int Arch Allergy Immunol 1998;115:270-277.